Background: TGF beta III receptor, or beta glycan, can function as an inhibin coreceptor with ActRII. TGF beta III receptor binds inhibin with high affinity and enhances binding in cells coexpressing ActRII and TGF beta III receptor. Inhibin forms crosslinked complexes with both recombinant and endogenously expressed TGF beta III receptor and ActRII. TGF beta III receptor confers inhibin sensitivity to cell lines that otherwise respond poorly to this hormone. The ability of TGF beta III receptor to inhibit or to facilitate inhibin antagonism of activin provides a variation on the emerging roles of proteoglycans as coreceptors modulating ligand receptor sensitivity, selectivity, and function. Beta arrestin 2 binds to TGF beta III receptor, triggered by phosphorylation of the receptor on its cytoplasmic domain, likely at threonine 841. Phosphorylation is mediated by TGFBR2, which is itself a kinase, rather than by a G protein coupled receptor kinase. Association with beta arrestin 2 leads to internalization of both receptors and downregulation of TGF beta signaling. The regulatory actions of beta arrestins are broader than previously appreciated, extending to the TGF beta receptor family as well.
Description: Rabbit polyclonal to TGFBR3
Immunogen: KLH conjugated synthetic peptide derived from TGFBR3
Specificity: ·Reacts with Human, Mouse, Pig, Dog and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 94 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-500;
·Immunocytochemistry: 1/100-200;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
